Combination therapy with VEGFR2 and EGFR siRNA enhanced the antitumor effect of cisplatin in non-small cell lung cancer xenografts

摘要：

　　siRNA targeting the murine VEGFR2 gene was designed and validated for efficient and robust silencing in vitro, and was then delivered by PEI in vivo to investigate the anti-tumor effect on non-small-cell lung cancer xenograffs.The following dosage regimens were tested for their tumor inhibitory effect in vivo: VEGFR2 siRNA, EGFR siRNA, VEGFR2 siRNA + EGFR siRNA, cisplatin alone, and VEGFR2 siRNA + EGFR siRNA + cisplatin.Targeted silencing of both VEGFR2 and EGFR expression by siRNA, combined with low dose cisplatin was found to effectively inhibit tumor growth, and extend the survival time of mice bearing the NSCLC xenografts.These results suggest that combination therapy using siRNAs and chemotherapy agents might offer a novel strategy for cancer treatment in the future.

关键词： siRNA vascular endothelial growth factor receptor 2 epidermal growth factor receptor chemotherapy agents

作者: Shah Chen Qian Xu Aimin Ji Xiaoxia Liu Wenfei Gong Huan Yang Daofei Luo Xialin Zuo Wenshi Li Ping Wu Li Liu

作者单位: Department of Pharmaceutical,Zhujiang Hospital,Southern Medical University,Guangzhou 510282,China

会议类型: 国内会议

会议名称: 2014年广东省药师周大会

会议地点: 广州

会议语种:英文

页码: 110-123

在线出版日期: 2014-01-11（万方平台首次上网日期，不代表论文的发表时间）